Department of Medicine
Faculty Profiles by Division

Division of Cardiology

Faculty Profiles

[Return To Index page]
photo Manling Zhang, MD, MS

Cardiology

Assistant Professor of Medicine

Email: zhangm5@upmc.edu

Contact
 
E-mail: zhangm5@upmc.edu
Education and Training
Education
MD, Shanghai Jiao Tong University School of Medicine, China, 1998
Training
Residency, Internal Medicine, Ruijin Hospital, Shanghai Jiangtong University, 2000
Residency, Internal Medicine, Medstar Good Samaritan Hospital, 2014
Chief Resident, Medstar Good Samaritan Hospital, 2014
Cardiovascular Fellowship, University of Pittsburgh, 2017
Advanced heart failure and transplant fellowship, University of Pittsburgh, 2018
Clinical Interest
Advanced heart failure and transplant
Publications
For my complete bibliography, Click Here.
Selected Publications:
Zhang M, Park SM, Wang Y, Shah R, Liu N, Murmann AE, Wang CR, Peter ME, Ashton-Rickardt PG. Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules. Immunity. 2006; 24(4): 451-61.
Zhang M, Liu N, Park SM, Wang Y, Byrne S, Murmann AE, Bahr S, Peter ME, Olson ST, Belaaouaj A, Ashton-Rickardt PG. Serine protease inhibitor 6-deficient mice have increased neutrophil immunity to Pseudomonas aeruginosa. J Immunol. 2007; 179(7): 4390-6.
Zhang M, Byrne S, Liu N, Wang Y, Oxenius A, Ashton-Rickardt PG. Differential survival of cytotoxic T cells and memory cell precursors. J Immunol. 2007; 178(6): 3483-91.
Zhang M, Koitabashi N, Nagayama T, Rambaran R, Feng N, Takimoto E, Koenke T, O'Rourke B, Champion HC, Crow MT, Kass DA. Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. Cell signal. 2008; 20(12): 2231-6.
Zhang M, Takimoto E, Hsu S, Lee DI, Nagayama T, Danner T, Koitabashi N, Barth AS, Bedja D, Gabrielson KL, Wang Y, Kass DA. Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. J Am Coll Cardiol. 2010; 56(24): 2021-30.
Zhang M, Kass DA. Phosphodiesterases and cardiac cGMP: evolving roles and controversies. Trends Pharmacol Sci. 2011; 32(6): 360-5.
Zhang M, Takimoto E, Lee DI, Santos CX, Nakamura T, Hsu S, Jiang A, Nagayama T, Bedja D, Yuan Y, Eaton P, Shah AM, Kass DA. Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling. Circulation. 2012; 126(8): 942-51.
Lee DI, Zhu G, Sasaki T, Cho GS, Hamdani N, Holewinski R, Jo SH, Danner T, Zhang M, Rainer PP, Bedja D, Kirk JA, Ranek MJ, Dostmann WR, Kwon C, Margulies KB, Van Eyk JE, Paulus WJ, Takimoto E, Kass DA. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature. 2015; 519(7544): 472-6.
Thapa D, Zhang M, Manning JR, Guimarães DA, Stoner MW, O'Doherty RM, Shiva S, Scott I. Acetylation of mitochondrial proteins by GCN5L1 promotes enhanced fatty acid oxidation in the heart. , Zhang M, Manning JR, Guimarães DA, Stoner MW, O'Doherty RM, Shiva S, Scott I. Am J Physiol Heart Circ Physiol. 2017; 313(2): H265-H274.
Nakamura T, Zhu G, Ranek MJ, Kokkonen-Simon K, Zhang M, Kim GE, Tsujita K, Kass DA. Prevention of PKG-1a Oxidation Suppresses Antihypertrophic/Antifibrotic Effects From PDE5 Inhibition but not sGC Stimulation. Circ Heart Fail. 2018; 11(3).
Sponsored Research/Activities
Title: the Impact of GCN5L1 on Cardiac Energetics in Heart Failure Development
Role: Principal Investigator
Funding Agency: Samuel and Emma Winters Foundation
Grant Number: RES
Start Year: 2019
End Year: 2020